OA11652A - Orally administered controlled drug delivery system providing temporal and spatial control. - Google Patents

Orally administered controlled drug delivery system providing temporal and spatial control. Download PDF

Info

Publication number
OA11652A
OA11652A OA1200100064A OA1200100064A OA11652A OA 11652 A OA11652 A OA 11652A OA 1200100064 A OA1200100064 A OA 1200100064A OA 1200100064 A OA1200100064 A OA 1200100064A OA 11652 A OA11652 A OA 11652A
Authority
OA
OAPI
Prior art keywords
pharmaceutical composition
composition
weight
drug
acid
Prior art date
Application number
OA1200100064A
Other languages
English (en)
Inventor
Himadri Sen
Naresh Talwar
John H Staniforth
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of OA11652A publication Critical patent/OA11652A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200100064A 1998-09-14 1999-01-19 Orally administered controlled drug delivery system providing temporal and spatial control. OA11652A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number Publication Date
OA11652A true OA11652A (en) 2004-12-08

Family

ID=22545063

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100064A OA11652A (en) 1998-09-14 1999-01-19 Orally administered controlled drug delivery system providing temporal and spatial control.

Country Status (40)

Country Link
EP (2) EP1281397A1 (is)
JP (1) JP2002524494A (is)
CN (1) CN1186013C (is)
AP (1) AP1659A (is)
AR (1) AR022672A1 (is)
AT (1) ATE245414T1 (is)
AU (1) AU758324B2 (is)
BG (1) BG105339A (is)
BR (1) BR9913696A (is)
CA (1) CA2343760A1 (is)
CO (1) CO5130022A1 (is)
CU (1) CU23040A3 (is)
CZ (1) CZ2001901A3 (is)
DE (1) DE69909801T2 (is)
DK (1) DK1107741T3 (is)
EA (2) EA004443B1 (is)
EE (1) EE200100153A (is)
ES (1) ES2204098T3 (is)
GE (1) GEP20043216B (is)
HR (1) HRP20010187B1 (is)
HU (1) HUP0103632A3 (is)
ID (1) ID29843A (is)
IL (1) IL141977A0 (is)
IS (1) IS5885A (is)
MX (1) MXPA01002634A (is)
MY (1) MY127952A (is)
NO (1) NO20011276L (is)
NZ (2) NZ523747A (is)
OA (1) OA11652A (is)
PE (1) PE20001058A1 (is)
PL (1) PL346798A1 (is)
PT (1) PT1107741E (is)
SI (1) SI1107741T1 (is)
SK (1) SK285478B6 (is)
SV (1) SV1999000152A (is)
TR (1) TR200100731T2 (is)
UA (1) UA73287C2 (is)
UY (1) UY25710A1 (is)
WO (1) WO2000015198A1 (is)
ZA (1) ZA995839B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1485A (en) * 2000-03-03 2005-10-31 Ranbaxy Laboratories Ltd Orally administered controlled delivery system for once daily administration of ciprofloxacin.
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2002011726A1 (en) * 2000-08-08 2002-02-14 Daiichi Pharmaceutical Co., Ltd. Highly absorbable solid preparation
IN192748B (is) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
MXPA04001388A (es) * 2001-08-16 2004-05-27 Oregon State Dispositivo de retencion gastrica expandible.
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
AU2002351798A1 (en) * 2001-10-29 2003-05-12 Labopharm Inc. Methods and dosage forms for improving the bioavailability of therapeutic agents
WO2003041656A2 (en) * 2001-11-13 2003-05-22 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
DE60117712T2 (de) 2001-11-19 2006-11-16 Lupin Ltd., Mumbai Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam-antibiotikums
EP1501521B1 (en) * 2002-04-23 2007-05-02 Lupin Limited Long acting compositions comprising zidovudine and/or lamivudine
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE602005025767D1 (de) * 2004-06-28 2011-02-17 Abbott Healthcare Products Bv Orale tedisamilformulierungen mit magenretentionseigenschaften und verzögerter freisetzung
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
CA2613407A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
DE602005007205D1 (de) * 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
JP2012500230A (ja) 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
EP3220894B1 (en) 2014-11-19 2021-03-10 DuPont Nutrition USA, Inc. Nanosuspension formulation
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
ES2861153T3 (es) 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
DK3628004T3 (da) 2018-06-27 2021-12-20 Amneal Complex Products Res Llc Selvregulerende osmotiske mave-tarm tilbageholdende leveringssystemer til lægemiddel
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
ID29843A (id) 2001-10-18
HRP20010187B1 (en) 2004-04-30
SK285478B6 (sk) 2007-02-01
HRP20010187A2 (en) 2002-04-30
HUP0103632A3 (en) 2005-06-28
PL346798A1 (en) 2002-02-25
HUP0103632A2 (hu) 2002-02-28
UA73287C2 (en) 2005-07-15
CA2343760A1 (en) 2000-03-23
DE69909801T2 (de) 2004-06-03
AP2001002098A0 (en) 2001-03-31
EE200100153A (et) 2002-06-17
ATE245414T1 (de) 2003-08-15
SV1999000152A (es) 2000-07-03
EA200300847A1 (ru) 2003-12-25
MY127952A (en) 2007-01-31
NO20011276L (no) 2001-05-10
EA200100346A1 (ru) 2001-10-22
CO5130022A1 (es) 2002-02-27
NZ510487A (en) 2003-04-29
DK1107741T3 (da) 2003-11-17
AU1779499A (en) 2000-04-03
EP1107741B1 (en) 2003-07-23
IL141977A0 (en) 2002-03-10
BG105339A (en) 2001-11-30
EP1107741A1 (en) 2001-06-20
GEP20043216B (en) 2004-04-26
NZ523747A (en) 2004-04-30
SK3472001A3 (en) 2001-10-08
WO2000015198A1 (en) 2000-03-23
JP2002524494A (ja) 2002-08-06
PE20001058A1 (es) 2000-10-05
AR022672A1 (es) 2002-09-04
AP1659A (en) 2006-09-06
NO20011276D0 (no) 2001-03-13
CN1186013C (zh) 2005-01-26
CZ2001901A3 (cs) 2001-08-15
BR9913696A (pt) 2001-10-09
HK1037967A1 (en) 2002-03-01
CN1325299A (zh) 2001-12-05
PT1107741E (pt) 2003-12-31
UY25710A1 (es) 2000-03-31
DE69909801D1 (de) 2003-08-28
TR200100731T2 (tr) 2001-06-21
ES2204098T3 (es) 2004-04-16
SI1107741T1 (en) 2004-02-29
AU758324B2 (en) 2003-03-20
ZA995839B (en) 2000-03-28
IS5885A (is) 2001-03-12
EA004443B1 (ru) 2004-04-29
EA005767B1 (ru) 2005-06-30
MXPA01002634A (es) 2002-06-04
CU23040A3 (es) 2005-04-14
EP1281397A1 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
US6960356B1 (en) Orally administered drug delivery system providing temporal and spatial control
EP1107741B1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
EP2238975B1 (en) Gastric retention controlled drug delivery system
US6899896B2 (en) Hydrogel-driven layered drug dosage form
EP1315478A2 (en) Controlled release formulation of erythromycin or a derivative thereof
WO2001064183A1 (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
HK1037967B (en) Orally administered controlled drug delivery system providing temporal and spatial control
HK1053422A (en) Orally administered controlled drug delivery system providing temporal and spatial control
AU2006201553A1 (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin